Mike Sovie, Executive Vice President, Sales and Marketing at Sentry, recently offered his perspective on the most significant takeaways from the ASHP Midyear Clinical Meeting in Las Vegas at the beginning of this month.
Lidia Rodriguez-Hupp, 340B Compliance Officer & Senior Vice President at Sentry and well-respected 340B thought leader, offered her views on what she considered the most provocative topics addressed at the 20th Annual 340B Coalition Conference last month.
The 340B Drug Pricing Program, established nearly 25 years ago, requires drug manufacturers to provide outpatient drugs to eligible health care providers at significantly discounted prices.
Now more than ever, the FBI is warning healthcare providers to guard against cyberattacks. Security experts say cybercriminals are increasingly targeting the $3 trillion U.S. healthcare industry, where many facilities are still reliant on aging computer systems that do not use the latest security features.
So why all the current fuss over population health and analytics? In my opinion three fundamental elements are driving our market.
You’ve probably already read a number of articles about HRSA’s proposed 340B Drug Pricing Program Omnibus Guidance and the expected impact of the proposed changes. Now, you need to act.
When it was announced that the Health Resources and Services Administration (HRSA) had withdrawn its long-awaited mega-reg, you may have momentarily breathed a sigh of relief.
Confused over the status of the 340B orphan drug exclusion? The last several months have been filled with continued controversy and back-and-forth legal action.